0001104659-16-129571.txt : 20160728 0001104659-16-129571.hdr.sgml : 20160728 20160627170930 ACCESSION NUMBER: 0001104659-16-129571 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20160627 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Syros Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001556263 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 453772460 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 480 ARSENAL STREET STREET 2: SUITE 130 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617-744-1340 MAIL ADDRESS: STREET 1: 480 ARSENAL STREET STREET 2: SUITE 130 CITY: WATERTOWN STATE: MA ZIP: 02472 FORMER COMPANY: FORMER CONFORMED NAME: LS22, Inc. DATE OF NAME CHANGE: 20120815 CORRESP 1 filename1.htm

 

VIA EDGAR

 

June 27, 2016

 

Ms. Suzanne Hayes

Assistant Director

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Mail Stop 4720

Washington, D.C. 20549

 

Re:                             Syros Pharmaceuticals, Inc. (the “Company”)

Registration Statement on Form S-1 File No. 333-211818

 

Ladies and Gentlemen:

 

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), and as representatives of the several underwriters of the Company’s proposed public offering of shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), we hereby join the Company’s request for acceleration of the effective date of the above-referenced Registration Statement, as amended, requesting effectiveness for 4:00 p.m. (ET) on June 29, 2016, or as soon thereafter as practicable.

 

Pursuant to Rule 460 of the Act, we wish to advise you that we have distributed approximately 941 copies of the Company’s preliminary prospectus relating to the Common Stock, dated June 20, 2016, through the date hereof to underwriters, dealers, institutions and others.

 

The undersigned, as representatives of the several underwriters, have complied and will continue to comply, and have been informed by the participating underwriters that they have complied and will continue to comply, with the provisions of Rule 15c2-8 of the Securities Exchange Act of 1934, as amended.

 

[Signature page follows]

 


 

 

Very truly yours,

 

 

 

 

 

COWEN AND COMPANY, LLC

 

PIPER JAFFRAY & CO.

 

 

Acting on their own behalf

 

 

and as representatives of several

 

 

underwriters

 

 

 

 

 

 

 

By:

COWEN AND COMPANY, LLC

 

 

 

 

 

 

 

By:

/s/ Jason Fenton

 

 

Name:

Jason Fenton

 

 

Title:

Managing Director

 

 

 

 

 

 

By: PIPER JAFFRAY & CO.

 

 

 

 

 

 

 

By:

/s/ Christie L. Christina

 

Name: Christie L. Christina

 

Title: Managing Director

 

[Signature Page to Acceleration Request]